Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Roche Axes Emugrobart in Obesity; Chugai to Revive SMA Program
Roche is discontinuing the development of Chugai Pharmaceutical-originated emugrobart (GYM329) in obesity and returning all rights to the drug, prompting the Japanese company to revive a spinal muscular atrophy (SMA) program that was dropped earlier this year. Chugai said on…
To read the full story
Related Article
BUSINESS
- Roche Axes Emugrobart in Obesity; Chugai to Revive SMA Program
September 29, 2026
- Shionogi’s Ensitrelvir Wins EU Approval for COVID-19 PEP
September 29, 2026
- Forxiga Most Pitched via 9 Promotion Channels in August: Intage
September 29, 2026
- Mikasa Bags Japan Rights to AFT’s Maxigesic IV
September 29, 2026
- BMS Taps Maruho’s Dermatology Strength to Maximize Sotyktu Value
September 29, 2026
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…